A cost effectiveness study establishing the impact and accuracy of implementing the NICE guidelines lowering plasma NTproBNP threshold in patients with clinically suspected heart failure at our institution by Webb, Jessica et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.ijcard.2017.10.126
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Webb, J., Draper, J., Rua, T. D. D. O., Yiu, Y., piper, S., Teall, T., ... Carr-White, G. (2018). A cost effectiveness
study establishing the impact and accuracy of implementing the NICE guidelines lowering plasma NTproBNP
threshold in patients with clinically suspected heart failure at our institution. International Journal of Cardiology,
257, 131-136. https://doi.org/10.1016/j.ijcard.2017.10.126
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
1 
 
A Cost Effectiveness study establishing the impact and accuracy of implementing the 1 
NICE guidelines lowering plasma NTproBNP threshold in Patients with clinically 2 
suspected Heart Failure at our Institution 3 
Jessica Webb BMBCh1,2, Jane Draper1, Tiago Rua1, Yee Yiu1, Susan Piper MBBS1,3, Thomas 4 
Teall MBBS1, Lauren Fovargue PhD2, Elena Bolca MBBS1, Tom Jackson MBBS1,2, Simon 5 
Claridge MBBS1,2, Ben Sieniewicz MBBS1,2, Bradley Porter MBBS1,2, Adam McDiarmid 6 
MD1 , Ronak Rajani MD1,2, Stamatis Kapetanakis MBBS1,2,  Christopher A Rinaldo PhD1,2, 7 
Reza Razavi MD1,2, Theresa A McDonagh PhD2,3, Gerald Carr-White PhD1,2 8 
Departments 9 
1 Department of Cardiology, Guy’s and St Thomas’ NHS Foundation Trust, London, SE1 10 
7EH. United Kingdom 11 
2 Division of Imaging Sciences and Biomedical Engineering, King’s College London, SE1 12 
7EH, United Kingdom  13 
3 Department of Cardiology, King’s College Hospital NHS Foundation Trust, London, SE5 14 
9RS 15 
All authors takes responsibility for all aspects of the reliability and freedom from bias of the 16 
data presented and their discussed interpretation 17 
Corresponding author contact information 18 
Dr Jessica Webb Division of Imaging Sciences and Biomedical Engineering, 4th floor 19 
Lambeth Wing, King’s College London, SE1 7EH, United Kingdom 20 
2 
 
Tel: +44 7970440562 21 
Email: Jessica.webb@kcl.ac.uk 22 
Funding 23 
The authors have received funding from the EU FP7 for research, technological development 24 
and demonstration under the grant agreement VP2HF (number 611823). The authors also 25 
acknowledge financial support from the Department of Health, via the National Institute for 26 
Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’ s & St 27 
Thomas’ NHS Foundation Trust in partnership with King’ s College London and King’ s 28 
College Hospital NHS Foundation Trust. 29 
Conflicts of Interest 30 
The authors have no relevant affiliations or financial involvement with any organization or 31 
entity with a financial interest in or financial conflict with the subject matter or materials 32 
discussed in the manuscript. 33 
Abbreviations 34 
HF  Heart failure 35 
LVEF   Left ventricular ejection fraction 36 
HFrEF  Heart Failure with reduced Ejection Fraction  37 
HFmrEF Heart Failure with mid range Ejection Fraction  38 
HFpEF Heart Failure with preserved Ejection Fraction  39 
3 
 
NTproBNP  N terminal pro-B-type natriuretic peptide  40 
NYHA  New York Heart Association  41 
ESC  European Society of Cardiology  42 
MCV  mean corpuscular volume  43 
PCV  packed cell volume 44 
GFR  glomerular filtration rate 45 
Keywords 46 
Heart Failure (HF) 47 
NTproBNP 48 
Heart Failure with reduced Ejection Fraction (HFrEF) 49 
Heart Failure with mid range Ejection Fraction (HFmrEF) 50 
Heart Failure with preserved Ejection Fraction (HFpEF)  51 
Word Count 2970 52 
  53 
4 
 
Abstract  54 
Aims 55 
The 2014 National Institute of Clinical Excellence (NICE) guidelines on the management of 56 
acute heart failure recommended using a plasma NT-proBNP threshold of 300pm/ml to assist 57 
in ruling out the diagnosis of heart failure (HF), updating previous guidelines recommending 58 
using a threshold of 400pg/ml. NICE based their recommendations on 6 studies performed in 59 
other countries. This study sought to determine the diagnostic and economic implications of 60 
using these thresholds in a large unselected UK population.  61 
Methods  62 
Patient and clinical demographics were recorded for all consecutive suspected HF patients 63 
over 12 months, as well as clinical outcomes including time to HF hospitalisation and time to 64 
death (follow up 15.8 months).  65 
Results 66 
Of 1995 unselected patients admitted with clinically suspected HF, 1683 (84%) had a 67 
NTproBNP over the current NICE recommended threshold, of which 35% received a final 68 
diagnosis of HF. Lowering the threshold from 400 to 300pg/ml would have involved 69 
screening an additional 61 patients and only would have identified one new patient with HF 70 
(sensitivity 0.985, NPV 0.976, Area under the curve (AUC) at 300pg/ml 0.67; sensitivity 71 
0.983, NPV 0.977, AUC 0.65 at 400pg/ml). The economic implications of lowering the 72 
threshold would have involved additional costs of £42,842.04 (£702.33 per patient screened, 73 
or £ 42,824.04 per new HF patient).  74 
Conclusion 75 
Applying the recent updated NICE guidelines to an unselected real world population 76 
increases the AUC but would have a significant economic impact and only identified one new 77 
patient with heart failure.  78 
 79 
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Introduction 80 
Evaluating and managing patients with acute dyspnoea remains challenging in the acute 81 
setting. Misdiagnosis of heart failure can lead to morbidity, mortality and increased resource 82 
utilization. 70% of heart failure costs are due to costs of hospitalisation and in total, heart 83 
failure costs in the United Kingdom are estimated to account for 2% of the total National 84 
Health Service (NHS) budget 1 2. Cost effective diagnosis and management of HF is of 85 
paramount importance.  86 
Plasma NTproBNP has been shown to be effective as a rule out test 3 4. In 2012 the European 87 
Society of Cardiology updated their guidelines on the diagnosis of acute heart failure 88 
recommending an optimal exclusion cut off point for NTproBNP of 300pg/ml 5. Two years 89 
later, this threshold was endorsed by NICE 6, updating previous guidelines recommending 90 
400pg/ml as a cut off 7, on the basis of 6 studies performed in Canada 8, The United States of 91 
America 9, The Netherlands 10, Switzerland 11 12 and Australia 13, that demonstrated benefit 92 
when comparing the use of peptides against standard care on mortality 9, length of stay in the 93 
Emergency Department 8-10, subsequent readmissions 8 9 11 12 and costs 8 9 11 12, Table 1. The 94 
latter three studies used the same randomised test data 11-13 and none of the costs or effects 95 
analysed were measured in a context directly applicable to a British NHS hospital 14. None of 96 
the trials showed any statistical difference in length of stay for initial hospitalisation, 97 
suggesting that the real economic benefit was found in the Emergency Department assessing 98 
which patients could be discharged.   99 
We sought to determine the accuracy and economic implications of reducing the threshold of 100 
NTproBNP to 300pg/ml in a NHS hospital in a large unselected population of heart failure 101 
patients admitted to a Tertiary Hospital in the United Kingdom with a large A and E 102 
department.  103 
Methods 104 
In our hospital we run a NTproBNP led heart failure service where all patients with suspected 105 
heart failure have a plasma NT-proBNP requested. A raised result automatically triggers a 106 
review by a HF nurse and if appropriate, an echocardiogram and HF consultant review within 107 
48 hours. There are clear local guidelines coupled with regular teaching sessions in both the 108 
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A&E department and on the wards, explaining the rationale for the use of peptide testing and 109 
that peptide testing in patients with known HF is not recommended. However, despite this, 110 
patients with known HF had their NTproBNP tested. The patients who had known HF and 111 
had a NTproBNP tested were included in the analysis as we felt it was important not to 112 
exclude the cost implications of real life interpretation of current guidelines.  113 
All consecutive patients who had plasma NT-proBNP tested in our institution over one year 114 
were included, between 10/09/2014 and 09/09/2015, Figure 1. The list of patients with 115 
NTproBNP tested because of suspected heart failure was checked against all heart failure 116 
patients from the same time period previously submitted NICOR dataset to ensure that all 117 
heart failure patients were identified. Clinically the heart failure team reviewed all patients 118 
with plasma NTproBNP >400ng/l and echocardiography was performed by a sonographer in 119 
line with current ESC guidelines 15, unless the patient had been scanned in the 6 months 120 
previously or the symptoms and investigations suggested an acute deterioration recently. 121 
Diagnoses were adjuciated through the heart failure multidisciplinary team. When patients 122 
were admitted more than once, their first chronological presentation was recorded. Data was 123 
collected as part of our Institution’s approved Clinical Audit.  124 
Assumptions in patients with NTproBNP 300-399pg/ml 125 
For this study, all patients with values between 0 and 399ng/l were also investigated using 126 
hospital databases and records to confirm diagnoses, patient demographics, risk factors, 127 
length of stay and time to heart failure hospitalisation. Diagnoses were adjuciated through the 128 
heart failure multidisciplinary team. 129 
It was noted that 6% of the patients with NTproBNP 400-499pg/ml did not have 130 
echocardiography performed within 48 hours, and it was assumed that the same proportion of 131 
patients in the NTproBNP 300-399pg/ml cohort would have the same. For this reason, only 132 
57 additional echo were included in the costs analysis. This parameter was subjected to one-133 
way deterministic analyses and exhibited little impact around the overall cost implications. 134 
For estimated length of stay (LOS), the one new patient who would have been diagnosed with 135 
heart failure if the NTproBNP threshold was reduced to 300pg/ml was assumed to have had 136 
the same length of stay as those patients with a new diagnosis of HF with NTproBNP 400-137 
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499pg/ml. This was based on the median LOS for patients with HF and NTproBNP 400-138 
499pg/ml of 6 days compared to 5 days for the patients without HF and NTproBNP 400-139 
499pg/ml.  140 
Moreover, it was assumed that diagnosing HF in the NTproBNP 300-399pg/ml cohort would 141 
alter subsequent readmission rates as patients with a new diagnosis of HF would be started on 142 
medical therapy with access to the HF team and education. Originally the plan had been to 143 
use readmission rates from published literature, assuming that if the threshold was lowered to 144 
300pg/ml, it could be infered from the IMPROVE-CHF trial 8 that the readmission rate would 145 
be 13%, and if the threshold was kept at 400pg/ml then the readmission rate for patients with 146 
BNP 300-399pg/ml would be comparable to the study’s ‘usual care group’ cohort with a 20% 147 
rate of readmission for the NTproBNP group and 20% for the control group. However, this 148 
trial (and the others referenced in the recent NICE guidelines) used different NTproBNPcut 149 
offs, two trials used the cut offs from the PRIDE study 3 900pg/ml 9 (and possibly 450pg/ml 150 
for the small number of patients under 50 years of age 8) and the other trial 1017pg/ml 10. As 151 
the data published was not comparable to our dataset, it was decided to use the patients with 152 
NTproBNP 400-499pg/ml as our reference cohort and assumed that the same rate of 153 
rehospitalisation would apply to patients without HF but with  NTproBNP of 300-399pg/ml. 154 
Over the 15.8 months (range 14.1-27.0), the rate of subsequent HF hospitalisation was 47.1% 155 
for patients with HF and NTproBNP 400-499pg/ml, compared to 57.6% with no HF and 156 
NTproBNP between 400-499pg/ml. This assumption was also used in the patients with 157 
NTproBNP 300-399pg/ml.  158 
NT-proBNP Assays 159 
NT-proBNP analysis was performed with the commercially available immunoassay using the 160 
Elecsys 1010, 2010, or E170 proBNP assay (Roche Diagnostics GmbH, Manheim, 161 
Germany). Details of the assays, cross-reactivity and coefficients of variation, have 162 
previously been reported 3 16.  163 
Cost and cost-effectiveness analyses 164 
The present cost analysis considers all heart failure related costs from an NHS and personal 165 
social services perspective. Wherever possible, NHS reference costs are used. With regards to 166 
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human resource costs, the hourly cost of the heart failure team was sourced from Personal 167 
Social Services Research Unit compendium 17. If unavailable, internal costs from our Tertiary 168 
Hospital in the United Kingdom are considered. The total costs were calculated by 169 
multiplying the frequencies by the respective unit cost. Cost-effectiveness analysis evaluates 170 
the cost per additional patient correctly diagnosed with heart failure. 171 
The cost of the NTproBNP sample at our institution was £32.64 18. The length of stay was 172 
recorded from hospital records and the cost of theoretical additional length of stay was based 173 
on information from the NHS reference Costs 19. The assumption from NICE was that 174 
patients stay an additional two days if they are falsely assessed as being likely or unlikely to 175 
have heart failure 6. The cost of the Heart Failure team was assumed to be an hour of time 176 
from a Band 7 clinical nurse (£53/hour) 17. No additional costs for other members of the heart 177 
failure team (consultant, dietician, pharmacist, junior doctors) were included for the patients 178 
without heart failure as it was assumed that the rest of the team would only review if a 179 
diagnosis of heart failure was made. With regards to patients with diagnosed Heart Failure, a 180 
cost of £334.00 was estimated, based on an average of 20 minutes per patient discussed and 181 
the presence of one consultant, one registrar and one nurse 17. The cost of an echocardiogram 182 
was £66 17.  183 
Statistical analysis 184 
Data is given as mean ± standard deviation (SD) when normally distributed, as median and 185 
interquartile range (Q1-Q3) for plasma NTproBNP and other data not normally distributed or 186 
skewed, and as frequencies and percentages for categorical variables. The primary endpoints 187 
were final diagnosis, length of stay and time to rehospitalisation. Associations between 188 
baseline variables were evaluated using 1 way analysis of variance, Mann-Whitney U, T-test 189 
and chi-square tests, where appropriate. The accuracy of using NTproBNP to detect HF was 190 
assessed using area under the curves, calculated using Prism with the optimal cut off defined 191 
as 90% sensitivity. Statistical significance was defined as a p value of <0.05.  192 
Results  193 
In total, 1995 patients with clinically suspected heart failure had NTproBNP tested of which 194 
20.7% had a final diagnosis of HF. 84% of these patients had a NTproBNP over the current 195 
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NICE recommended threshold for ruling out heart failure, of which 24% were diagnosed with 196 
HF (1683 had NTproBNP >400pg/ml (84.3%), 61 had NTproBNP between 300-400pg/ml 197 
(3.1%), and 251 had NTproBNP <300pg/ml (12.6%). In total, 413 new cases of acute HF 198 
were diagnosed (mean age 72.3 ± 14.8 years, 57% male) with 47.9% Heart Failure with 199 
reduced Ejection Fraction (HFrEF), 22.0% Heart Failure with mid range Ejection Fraction 200 
(HFmrEF), 21.8% Heart Failure with preserved Ejection Fraction (HFpEF) and 8.2% right 201 
ventricular systolic dysfunction (RVSD). Only one of the 61 patients with NTproBNP 202 
between 300-399pg/ml, was diagnosed with HF.  203 
Despite clear guidance and regular education, 284 patients with known HF had NTproBNP 204 
tested on admission. 205 
At 300pg/ml the sensitivity was 0.985, specificity was 0.153 with a negative predictive value 206 
(NPV) of 0.976 and positive predictive value (PPV) of 0.233. The area under the curve 207 
(AUC) was 0.67 (95% CI 0.64-0.70) and optimal cut off 837.5pg/ml. Using a threshold of 208 
400pg/ml, sensitivity was 0.983, specificity was 0.188, NPV 0.977 and PPV 0.240. The AUC 209 
was 0.65 (95% CI 0.62-0.68) and optimal cut off 857.0pg/mL. The difference in AUC was 210 
not significant (p=0.47). The theoretical number of patients not identified by increasing 211 
NTproBNP thresholds is shown in Figure 2. This illustrates that the lower NTproBNP are 212 
recorded in patients with HFpEF and RVSD. For all new HF patients, the AUC was 213 
calculated to be 0.73 (95% CI 0.70-0.75) with 786pg/ml as the optimal cut off.  214 
The economic implications of theoretically lowering the threshold to 300pg/ml would have 215 
cost £90,821.08 compared to the current clinical model, with a NTproBNP threshold of 216 
400pg/ml, that costs £47,979.04, Table 2. One way deterministic sensitivity analyses were 217 
performed to the proportion of patients that underwent an echocardiogram, varying from the 218 
baseline (57 additional echocardiograms performed) to the minimum (only half of patients, 219 
i.e. 30 additional echocardiograms) and maximum (61 additional echocardiograms, i.e. every 220 
patient). These changes have little impact in the overall cost implications. The baseline total 221 
cost difference per patient screened (£690.67) marginally decreases and increases in the 222 
minimum (£661.46) and maximum scenarios (£695.00), respectively. As the cost 223 
implications were small, we continued the assumption of 57 echocardiograms, which equated 224 
to a difference of £42,842.04 or £702.33 per patient screened. With regards to the cost-225 
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effectiveness analysis, a total cost of £42,842.04 per additional patient identified with heart 226 
failure is estimated.  227 
Discussions 228 
The recent updated NICE guidelines to lower the plasma NT-proBNP threshold of 300ng/litre 229 
to rule out the diagnosis of heart failure increased the AUC and would have had a significant 230 
impact on the heart failure team and costings, with only 1 new patient with HF identified. The 231 
additional costs are £42,842.04 over the year, £702.33 per patient screened and in terms of 232 
cost effectiveness, for one new HF patient identified £42,842.04/patient. Of the 1995 233 
unselected patients assessed with clinically suspected heart failure 20.7% had a final 234 
diagnosis of HF made.  235 
Our study is the first to demonstrate the accuracy and economic implications and diagnostic 236 
implications of lowering the threshold of NTproBNP in a real life unselected clinical scenario 237 
in the United Kingdom. The NICE recommendations were based on 6 studies (Table 1) that 238 
demonstrated cost savings using peptides against standard clinical care that were not based in 239 
the United Kingdom with much higher cut offs for NTproBNP than are used clinically in our 240 
practice. IMPROVE-CHF 8 and the study performed by Siebert et al 9, used 900pg/ml, the 241 
same cut off as the PRIDE study 3 (and possibly 450pg/ml for the small number of patients 242 
under 50 years of age in IMPROVE-CHF) and Rutten et al, used 1017pg/ml 10. The reduction 243 
in costs were largely explained by a reduction of time in the Emergency Department and a 244 
reduction of echocardiography required for patients with NTproBNP under their defined 245 
threshold. Despite significant advances in our understanding of introducing peptides to 246 
clinical care, none of these studies addressed the issue of the economical implications of 247 
lowering the threshold as this was not their study objective. Moreover, the trial practice was 248 
not in line with the recent recommendations to increase access to echocardiography for 249 
patients with a suspicion of heart failure and raised peptides within 48 hours (infact one trial 250 
explicity stated the opposite, that echocardiography was not performed if the NTproBNP 251 
elevated and diagnosis presumed to be heart failure). Furthermore, three of the trials (that 252 
used the same clinical dataset) found more heart failure patients diagnosed in the standard 253 
clinical care cohort. Another issue with these studies was the short length of follow up, with 254 
studies being conducted for 30 days, 60 days, 120 days or at longest 360 days. Only one 255 
study in Swedish has been published considering the economic implications of lowering the 256 
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NTproBNP threshold from 400 to 300pg/ml in 14,346 patients 20. However the clinical 257 
questions addressed was whether it was cost effective to test NTproBNP before 258 
echocardiography, and not what other cost implications there would be with changing the 259 
threshold. Patients were identified from the central laboratory and costs of the blood tests and 260 
echocardiography were retrieved from the official fee schedule of one of the Swedish regions. 261 
They found that with a strict sequential testing strategy that there could be substantial cost 262 
reductions, with a major saving seen in younger patients. The authors found that costs were 263 
reduced by more using 400pg/ml as the cut-off (33-36% reduction when 400pg/ml the 264 
threshold compared to 28-29% with 300pg/ml).  265 
One of the striking findings of our study was the overall poor adherence to the guidelines in 266 
real life practice. We estimate that £9269.76 could have been saved if patients with known 267 
heart failure did not have NTproBNP checked. Despite evidence that NTproBNP can be used 268 
to predict prognosis, in our hospital the Seattle heart failure score is used that does not 269 
depend on NTproBNP results 21 and so NTproBNP is not currently indicated in our institution 270 
in patients with known HF. Moreover, the trials references by NICE were designed to test 271 
natriuretic peptides in the Emergency department, whereas in this real life practice, 25% of 272 
the patients presenting with acute heart failure were actually diagnosed on the hospital wards, 273 
Figure 1. The 2014 NICE guidelines 6 suggest that of the patients not idenitifed initially with 274 
acute heart failure, 80% will be identified during their admission and the remaining 20% will 275 
have a higher readmission rate over the following three months. The pressures on the four 276 
hour A&E waiting times, the number of acute medical beds as well as changes in the 277 
structure of the medical take may all contribute to over a quarter of the acute patients 278 
identified on the medical wards. Furthermore, there were 1298 patients who were suspected 279 
of having HF and had NTproBNP tested, but were found not to have HF. Although this 280 
number initially appears high, this represents only 0.7% of the total proportion of patients 281 
presenting to our Accident and Emergency (A&E), given that 182,720 adults were seen with 282 
26,779 medical inpatient admissions at our institution over the same time scale 22. There are 283 
two points that should be highlighted, first, is the number of patients with suspected HF but 284 
who are diagnosed with another condition appropriate or could this be reduced, and second, is 285 
the number of patients being seen in A&E, and being admitted in our institution, in line with 286 
previously published literature. Addressing the first point, the number patients with elevated 287 
NTproBNP but without HF are possibly elevated as in our institution, a raised NTproBNP 288 
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results in an automatic referral to the HF team. There has been considerable progress made 289 
recently through education events in both the medical and A&E departments to implement 290 
and explain the rationale for guidelines and NTproBNP testing, and to prevent unnecessary 291 
testing (of note, the cost of testing NTproBNP in patients without HF was £42,366.72). It is 292 
important to emphasize that our results reflect our real life experience of using NTproBNP.  293 
The second point is that the number of patients admitted with HF is lower than the 5% all 294 
emergency hospital admissions reported in the 2010 NICE guidelines 7, that was based on 295 
two publications from 2002. Indeed, it is lower than recent Accident and Emergency 296 
Statistics that suggest cardiorespiratory conditions were the 6th and 7th most common reason 297 
for an emergency presentation in the United Kingdom 23.  More work is needed to understand 298 
this further, and whether the populations are  comparable.  299 
The patients were not separated into those tested immediately in A&E and those tested on the 300 
medical wards as we found that patients were moved through to the wards quickly. Of the 301 
patients with NTproBNP 300-399pg/ml, only three were tested on the medical wards once 302 
their initial diagnosis had been disproved.  303 
The strengths of the study are that all patients were included who had NTproBNP tested and 304 
so the analysis represents real life practice. In addition, the costs and infrastructure are 305 
comparable to other UK hospitals. From an economic point, the modelling was based on the 306 
costs of tests, staff time and length of stay in line with the NICE suggestion that an elevated 307 
NTproBNP resulted in additional length of stay irrespective of the final diagnosis. We have 308 
not taken into account the economic or health benefits of early diagnosis and would need to 309 
address this prospectively. Weaknesses of the study are that our population included all 310 
patients clinically suspected of having HF from both the A&E/acute admission units and also 311 
the hospital wards, although this was only 3 patients in the NTproBNP300-399pg/ml 312 
category.. Even though this is not directly equivalent to studies published, the economic 313 
implications of lowering the threshold are still applicable. In addition, our study compared 314 
real-life practice with guideline directed practice, which will often vary. Patients who 315 
presented to other hospitals with HF readmissions were not included in the analysis. The 316 
inherent varibaility of NTproBNP was not directly considered, which is relevant when the 317 
reference change value has been shown to be 70.7% in health volunteers and 61.7% in 318 
patients with HF 24, with increased accuracy seen in Asian patients 25. Moreover, our hospital 319 
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run a NTproBNP led HF service which is not necessarily comparable to other NHS hospitals, 320 
as it may have resulted in additional patients having NTproBNP tested. Despite these 321 
important limitations, our results are important as they demonstrate the additional costs of 322 
lowering the NTproBNP threshold in our institution with only 1 additional patient with HF 323 
being identified.  324 
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Table 1: Published Literature reference in updated NICE guidelines assessing economic implications of lowering the threshold for NTproBNP 
in the assessment of acute heart failure 
Authors Peptide Clinical 
Environment 
Follow up Patients Costs based on Findings Issues when comparing to our NHS model 
Siebert et al, 2006 (8) NTproBNP Emergency 
Department (ED) 
– prospective, not 
randomised 
60 days 599 
patients 
presenting 
with 
dyspnoea 
Massachusetts General 
Hospital accounting 
database 
-NT proBNP model was more effective and less costly 
than standard clinical assessment 
-1.6% relative reduction of serious adverse event risk 
(from 25.8% to 25.4%) 
-9.4% reduction in costs (savings $474/patient) compared 
to standard care: reduce echocardiography by 58%, 
prevent 13% hospitalisations, reduce LOS by 12% 
-1% relative reduction in post discharge mortality 
-Used >900pg/ml as NTproBNP cut off following results 
from PRIDE 
-No echocardiograms performed below NTproBNP cut 
off or if NTproBNP elevated and primary diagnosis 
thought to be CHF (not PE). This is fundamentally 
different to our current practice 
-Costs very different to UK: echo costed as $247 
compared to £65.70 
Rutten et al, 2006 (9) NTproBNP Emergency 
Department (ED) 
– prospective, not 
randomised 
30 days 477 
patients 
with acute 
dyspnoea 
Erasmus Medical 
College, Rotterdam, 
the Netherlands 
-Reduction in median overall time to discharge from 3.4 
(IQR 0.6-11) days with standard care to 1.9 days (IQR 
0.12-8.4) with NTproBNP: No difference in duration of 
hospitalisation for 62/67% of patients admitted 
-Trend to reduction in costs $1364/patient (95%CI -246-
3215) 
-No difference in 30 day mortality 
-Rule out HF <93 (males), <144 (females) pg/ml; Ruling 
in HF > 1017pg/ml 
-Reduction in cost explained by difference in 
hospitalisation rate 
-Median LOS only reduced when factored in 
approximately 1/3 of patients who were not admitted 
Moe et al, IMPROVE 
CHF, 2007 (7) 
NT proBNP 7 Emergency 
Departments 
60 days 500 
patients 
with 
dyspnoea 
Canadian Institute of 
Health Information 
costing methodology 
-Reduction in median duration of ED visit from 6.3 (4.3-
8.6) to 5.6 (4-8) with NTproBNP 
-Reduction in patients rehospitalised by 60 days from 
20% to 13% 
-Reduction in costs from US $6129 to US $5180 
- Used NTproBNP cut off from PRIDE but not clarified if 
>450pg/ml was used for patients <50 years old 
(although mean age 70, SD 15 and range 20-96 so 
small number of patients) 
-No decision analytic framework analyses 
 
Mueller et al, 2006 
(10) 
BNP 
 
Emergency 
Department, 
randomized 
controlled single 
blind trial 
180 days 452 
patients 
with acute 
dyspnoea, 
man age 
71 years, 
42% 
female 
Costs standardised to 
according to the actual 
rates for patients with 
general insurance who 
were living in Basel 
-Reduction in initial hospital admission rate 
-Reduction in use of ITU 
-Reduction in median total days in the hospital at 180 
days (10 days (2-24) with BNP, 14 days (6-27 with 
standard care) 
-Reduction in total cost 
-BNP <100pg/ml rule out, rule in if > 500pg/ml 
-More patients in the control group were diagnosed with 
HF than in the BNP group (51% v 45%) and COPD 
more common in BNP group than in controls (23% v 
11%) 
-Reasons for improved LOS and economic outcome in 
BNP group, as same number of HF patients. Is it that 
patients without HF in BNP group are better identified 
and given alternative treated as they have low BNP 
Breidhardt et al, 2007 
(11) 
Mortality at 
720 days, 
morbidity and 
economic 
data at 360 
days 
-No effect on mortality at 720 days 
-Differences in length of stay and economic outcome 
improved in BNP group, with no change in NYHA status. 
AHTA  (Adelaide 
Health Technology 
Assessment), 2007 
(12) 
180 days Population considered 
to be similar and costs 
considered to be 
applicable to Australian 
Healthcare 
-Cost savings for 100 patients = A$ 33,849 (95% CI A$ 
304-A$ 67,393) 
-Cost savings on A$ 338 per patients presenting to ED 
with acute dyspnoea 
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Table 2: Economic costings for two NTproBNP models 
Model screening patients with BNP 300-399 pg/ml Number of 
patients 
Cost (£) per 
Intervention 
Comments  
Cost of Plasma NTproBNP blood tests  61   £32.64   £1,991.04   
Heart Failure Team initial reviews  61   £53.00   £3,233.00  One hour assumed (£53 cost assumed) 
Number of additional echocardiograms performed  57   £66.00   £3,762.00   
Additional length of stay  55   £604.00   £33,220.00  2 extra LOS days (costed at £302/day) 
Heart Failure Team Management for 1 new patient  1   £334.00   £334.00  Hourly cost of consultant, registrar and nurse are, respectively: £104; £71 and 
£53 (assumed 20 minutes/patient). 
Change in stay for patient correctly identified as having HF 
(Median LOS for HF patients 6 days, IQR 1-14) 
 1   £302.00   £302.00  1 extra day (costed at £302/day) 
Readmissions for 1 HF patient (assume LOS 6 days)  0.5   £302.00   £142.24  Assumed that 47.1% of 1 patients will be readmitted and stay for extra 6 days 
(costed £302/day)  
Readmissions for not HF patients (assume LOS 5 days)  31.7   £1,510.00   £47,836.80  Assumed that 57.6% of 55 patients will stay for extra 5 days (costed £302/day) 
TOTAL  £                                             90,821.08   
Model screening patients with BNP > 400pg/ml (not 
screening patients with BNP 300-399pg/ml) 
Number of 
patients 
Cost (£) per 
Intervention 
Total Costs (£) Comments 
Readmissions for 55 patients with NTproBNP 300-399 and 
not HF (assuming LOS 5 days) 
31.7  £1,510.00   £47,836.80  Assumed that 57.6% of 55 patients will stay for extra 5 days (costed £302/day) 
Readmissions for 1 patients with NTproBNP 300-399 and HF 
(assuming LOS 6 days) 
0.5  £302.00   £142.24   
TOTAL  £                                             47,979.04   
OVERALL TOTAL DIFFERENCE  £                                             42,842.04   
     
OVERALL TOTAL DIFFERENCE PER PATIENT SCREENED  £                                                  702.33   
     
COST PER ADDITIONAL PATIENT IDENTIFIED WITH HF  £     £                                                      7,021.80  
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